MolDX: Melanoma Risk Stratification Molecular Testing

Molecular diagnostic tests for melanoma risk stratification are covered only for patients with a personal history of melanoma who are undergoing workup or treatment evaluation, are nonmetastatic, have stage T1b+ (or T1a with inadequate microstaging), and have a presumed SLNB risk >5% with disease parameters within the test's intended use. Coverage also requires that the specific test has peer-reviewed clinical validity, demonstrated clinical utility beyond standard clinical/histological/radiographic factors, appropriate analytical validity, and performance equivalent or superior to similar covered tests.

"Patient has a personal history of melanoma."

Sign up to see full coverage criteria, indications, and limitations.